

dolutegravir

DTG 50mg



- The above chart shows 12 MPP licensees are developing DTG 50mg, of which:
  - Seven companies have filed with WHO-PQ; of which **Cipla, Hetero** and **Mylan** have received approvals
  - Eight companies have filed with USFDA; of which **Aurobindo, Cipla** and **Mylan** have received approvals
- **Sun Pharma** has received Expert Review Panel (ERP) approval
- In total, **five companies** are ready to supply DTG 50mg

DTG 50mg: Country-wise Filing Status

Approved (17) 60.6% PLHIV in LMICs	
Botswana	Nicaragua
Cambodia	South Africa
Congo	Tanzania
DR Congo	Uganda
Côte d'Ivoire	Ukraine
India	Uzbekistan
Kenya	Zambia
Malawi	Zimbabwe
Myanmar	

Filed (20) 25.6% PLHIV in LMICs	
Burundi	Namibia
Cameroon	Nigeria
El Salvador	Pakistan
Ethiopia	Peru
Gabon	Philippines
Ghana	Rwanda
Guyana	Senegal
Kyrgyzstan	Sierra Leone
Mauritius	Tajikistan
Mozambique	Vietnam

Generic DTG has been filed in 37 countries, of which approval is received from 17. Another 13 filings are planned from 2019 onwards, covering an additional 12.3% of people living with HIV (PLHIVs) in LMICs.

DTG dispersible tablets



- Three MPP licensees are developing DTG dispersible formulation, of which:
  - Two plan to file with WHO-PQ in Q4-19 and one in Q2-20
  - One plans to file with USFDA in Q4-19 and another one in Q1-20

TDF/3TC/DTG
(TENOFOVIR DISOPROXIL/LAMIVUDINE/DOLUTEGRAVIR)



- 14 MPP licensees are currently developing TDF/3TC/DTG, of which:
  - Seven have filed with WHO-PQ; of which **Mylan** has received approval
  - Eight have filed with USFDA; of which **Aurobindo, Hetero** and **Mylan** have received approvals
- **Cipla, Macleods, Laurus** and **Sun** have received ERP approvals
- In total, **seven companies** are ready to supply TLD

TDF/3TC/DTG: country-wise filing status

Approved (14) 68.9% PLHIV in LMICs	
Benin	Nigeria
Botswana	South Africa
Congo	Tanzania
Côte d'Ivoire	Uganda
India	Uzbekistan
Kenya	Zambia
Malawi	Zimbabwe

Filed (24) 19.5% PLHIV in LMICs		
Burkina Faso	Ghana	Niger
Burundi	Haiti	Philippines
Cambodia	Madagascar	Rwanda
Cameroon	Mali	Senegal
DR Congo	Mauritius	Sudan
El Salvador	Mozambique	Thailand
Ethiopia	Namibia	Ukraine
Gabon	Nepal	Vietnam

Generic TLD has been filed in 38 countries, of which approval is received from 14. Another 13 filings are planned from 2019 onwards (covering an additional 10.6% PLHIVs in LMICs).

TAF/FTC/DTG
(TENOFOVIR ALAFENAMIDE/EMTRICITABINE/DOLUTEGRAVIR)



- Due to lack of clinical data, TAF is not on the WHO Guidelines as of now. However, generics have already started developing TAF combinations
- 11 MPP licensees are developing TAF/FTC/DTG, of which:
  - **Mylan** has filed with USFDA and received approval
  - Another licensee has filed with USFDA in Dec 2018
- We anticipate development by additional licensees to accelerate once there is an update on WHO's position about use of TAF-containing formulations